Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
Saved in:
| Title: | Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). |
|---|---|
| Authors: | Dercle L; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: derclel@mskcc.org., Geyer S; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, USA., Nixon AB; Duke Cancer Institute, Duke University, Durham, USA., Innocenti F; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, USA., Shi Q; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, USA., Jacobson SB; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, USA., Luk L; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA., Liu A; Department of Physics, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, USA., Yang H; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA., Wen Y; Alliance Protocol Operations Office, University of Chicago, Chicago, USA., Zhao B; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA., Eche T; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA; Department of Radiology, Toulouse Rangueil Hospital, Toulouse, France., Mokrane FZ; Department of Radiology, Toulouse Rangueil Hospital, Toulouse, France., Yang M; Department of Radiology, New York-Presbyterian/Columbia University Irving Medical Center, New York, USA; McGovern Medical School at University of Texas Health Science Center Houston, Houston, USA., Meyerhardt J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Medical College of Cornell University, New York, USA., Venook AP; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, USA., Schwartz LH; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Abou-Alfa GK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. |
| Source: | ESMO open [ESMO Open] 2025 Dec; Vol. 10 (12), pp. 105848. Date of Electronic Publication: 2025 Dec 02. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
